Literature DB >> 20668267

Approval of provenge seen as first step for cancer treatment vaccines.

Vicki Brower.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20668267     DOI： 10.1093/jnci/djq295

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  13 in total

1.  Progress against cancer (1971-2011): how far have we come?

Authors:  A K Tiwari; H K Roy
Journal:  J Intern Med       Date:  2011-10-20       Impact factor: 8.989

Review 2.  Gene therapy for lung neoplasms.

Authors:  Anil Vachani; Edmund Moon; Elliot Wakeam; Andrew R Haas; Daniel H Sterman; Steven M Albelda
Journal:  Clin Chest Med       Date:  2011-10-07       Impact factor: 2.878

Review 3.  Cancer immunotherapy: sipuleucel-T and beyond.

Authors:  Aimee E Hammerstrom; Diana H Cauley; Bradley J Atkinson; Padmanee Sharma
Journal:  Pharmacotherapy       Date:  2011-08       Impact factor: 4.705

4.  Relationship of therapeutic cancer vaccine development to population disease burden and five-year survival.

Authors:  Elias J Dayoub; Matthew M Davis
Journal:  Hum Vaccin       Date:  2011-11-01

5.  Quantitative T cell repertoire analysis by deep cDNA sequencing of T cell receptor α and β chains using next-generation sequencing (NGS).

Authors:  Hua Fang; Rui Yamaguchi; Xiao Liu; Yataro Daigo; Poh Yin Yew; Chizu Tanikawa; Koichi Matsuda; Seiya Imoto; Satoru Miyano; Yusuke Nakamura
Journal:  Oncoimmunology       Date:  2015-01-07       Impact factor: 8.110

Review 6.  Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma.

Authors:  Christopher Schutt; Klaus Bumm; Leonardo Mirandola; Giovanni Bernardini; Nicholas D' Cunha; Lukman Tijani; Diane Nguyen; Joehassin Cordero; Marjorie R Jenkins; Everardo Cobos; W Martin Kast; Maurizio Chiriva-Internati
Journal:  Int Rev Immunol       Date:  2012-02       Impact factor: 5.311

Review 7.  Immuno-Oncology Medicines: Policy Implications and Economic Considerations.

Authors:  Georges Adunlin; Stefanie P Ferreri; Jenny Dong; Maisha Kelly Freeman
Journal:  Innov Pharm       Date:  2019-08-08

8.  Therapeutic response in patients with advanced malignancies treated with combined dendritic cell-activated T cell based immunotherapy and intensity-modulated radiotherapy.

Authors:  Kenichiro Hasumi; Yukimasa Aoki; Ryuko Watanabe; Kim G Hankey; Dean L Mann
Journal:  Cancers (Basel)       Date:  2011-04-28       Impact factor: 6.639

9.  Clinical response of advanced cancer patients to cellular immunotherapy and intensity-modulated radiation therapy.

Authors:  Kenichiro Hasumi; Yukimasa Aoki; Ryuko Wantanabe; Dean L Mann
Journal:  Oncoimmunology       Date:  2013-10-17       Impact factor: 8.110

10.  A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer.

Authors:  Paul Lr Mitchell; Michael A Quinn; Peter T Grant; David G Allen; Thomas W Jobling; Shane C White; Anne Zhao; Vaios Karanikas; Hilary Vaughan; Geoffrey Pietersz; Ian Fc McKenzie; Sharron E Gargosky; Bruce E Loveland
Journal:  J Immunother Cancer       Date:  2014-06-18       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.